Health chief 'disappointed' with cancer drug company

The chief executive of health watchdog Nice told ITV News he is "disappointed" that drug manufacturer Roche has not offered the NHS a discount on a breast cancer drug that costs around £90,000 per patient.

Kadcyla, which extends women's lives by almost six months, could be blocked from routine NHS access because it is too expensive.

"Companies can discount their prices and they frequently do. Given the list price. I would have expected the company to have at least considered (a discount)," Andrew Dillon said.

Advertisement

'Unaffordable' breast cancer drug set to be blocked

A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.